3-Minute Ed Book (2013)

Nathan Pennell, MD, PhD, ASCO Educational Book Associate Editor, discusses the importance of communication between oncologists and their patients in low-resource areas with Matjaz Zwitter, MD, PhD.

Apostolia M. Tsimberidou, MD, PhD, University of Texas MD Anderson Cancer Center, reviews strategies to overcome clinical, regulatory, and financial challenges in the implementation of personalized medicine.

Anjali S. Advani, MD, The Cleveland Clinic Lerner College of Medicine, reviews the treatment of young adults with acute lymphocytic leukemia.

Howard H. Bailey, MD, University of Wisconsin Carbone Cancer Center, reviews green tea polyphenols and their relation to GU cancer chemoprevention.

Richard D. Carvajal, MD, Memorial Sloan-Kettering Cancer Center, reviews surveillance options for patients with uveal melanoma following definitive management.

Winson Y. Cheung, MD, MPH, British Columbia Cancer Agency, reviews issues that affect optimal adherence to oral anticancer agents.

Don S. Dizon, MD, ASCO Educational Book Editor, discusses the importance of communication between an oncologist and their patients with Mary C. Politi, PhD, Washington University in St Louis, and Anthony L. Back, MD, University of Washington, Fred Hutchinson Cancer Research Center.

Nagi S. El Saghir, MD, Breast Center of Excellence, Naef K. Basile Cancer Institute, American University of Beirut Medical Center, discusses how to become involved in ASCO's international programs.

Claire Harrison, DM, Guy's and St Thomas' NHS Foundation Trust discusses the role of JAK1/2 Inhibitors in the treatment of chronic myeloproliferative neoplasms.

Dawn L. Hershman, MD, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, discusses the disparities and challenges in adherence to oral antineoplastic agents.

Thomas W. Leblanc, MD, MA, Duke Cancer Institute, discusses the ethics of health information technology in oncology.

Mark R. Litzow, MD, Division of Hematology, Mayo Clinic, reviews monoclonal antibody-based therapies in the treatment of ALL.

Georgina V. Long, MD, PhD, Melanoma Institute Australia, discusses multidisciplinary approach to brain metastasis from melanoma.

Graham W. Warren, MD, PhD, Hollings Cancer Center, Medical University of South Carolina, discusses tobacco and lung cancer.

Lillian L. Siu, MD, Princess Margaret Cancer Centre, discusses the selection of the best drugs for phase I clinical development.

Joshua D. Schiffman, MD, Huntsman Cancer Institute, University of Utah, discussing the connection of molecular pathways to hereditary cancer risk syndromes.

Blase N. Polite, MD, University of Chicago, reviews achieving health equity in colorectal cancer.

Hyman Muss, MD, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, discusses treatment approaches for older patients with stage II/III colorectal cancer.

Kathleen N. Moore, MD, Stephenson Cancer Center, University of Oklahoma, reviews ovarian cancer in older women.

Michael J. Mauro, MD, Knight Cancer Institute, Oregon Health & Science University, discusses resistance in chronic myelogenous and leukemia and overcoming it.